pyrazines has been researched along with threonine in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Shu, CK | 1 |
| Biggs, JR; Garcia, M; Kraft, AS; Peterson, LF; Zhang, DE; Zhang, Y | 1 |
| Morris, AP; Sellin, JH; Umar, S; Wang, Y | 1 |
| Ludwig, A; Meiners, S; Stangl, K; Stangl, V | 1 |
| Allievi, C; Berkers, C; Bernareggi, A; Bussolati, B; Camussi, G; Cassin, M; Coscia, M; Costa, G; de Feudis, P; di Giovine, S; Ferracini, R; Ferrero, D; Giai, V; Hunter, K; Inghirami, G; Jones-Bolin, S; Massaia, M; Neri, A; Nicoli, P; Ovaa, H; Palumbo, A; Peola, S; Pescalli, N; Pezzoni, G; Piva, R; Roato, I; Ruggeri, B; Strepponi, I; Tamagno, I; Williams, M; Zhao, H | 1 |
| Berenson, JR; Bonavida, B; Chen, H; Li, M; Li, ZW; Sanchez, E; Shen, J; Steinberg, JA; Wang, C | 1 |
| Kay, LE; Ruschak, AM; Schimmer, AD; Slassi, M | 1 |
| Appel, A | 1 |
| Gallastegui, N; Groll, M | 1 |
| Hu, Y; Wu, P; Zhang, J | 1 |
| Camidge, DR; Ching, KA; Christensen, JG; Clark, JW; Diamond, JR; Eckhardt, SG; Kanteti, R; Lira, ME; LoRusso, PM; Salgia, R; Schoenmakers, EF; Varella-Garcia, M; Wilner, K; Xu, LG | 1 |
| Clardy, J; Currie, CR; Nascimento, FS; Paludo, CR; Pupo, MT; Ruzzini, AC; Silva-Junior, EA | 1 |
| Cao, Y; Tong, J; Xu, Y; Zhang, L | 1 |
| Liu, L; Xu, J; Yu, H; Zhang, W | 1 |
| Hu, M; Rao, Z; Shao, M; Xu, M; Yang, C; Yang, T; Yi, G; You, J; Zhang, R; Zhang, X | 1 |
| Berglöf, A; Estupiñán, HY; Mohammad, DK; Schaafsma, GCP; Shi, Y; Smith, CIE; Vihinen, M; Wang, Q; Yu, L; Zain, R; Zhou, L | 1 |
3 review(s) available for pyrazines and threonine
| Article | Year |
|---|---|
Proteasome inhibitors: poisons and remedies.
Topics: Binding Sites; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Endothelium, Vascular; Humans; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Threonine | 2008 |
Novel proteasome inhibitors to overcome bortezomib resistance.
Topics: Allosteric Site; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Chloroquine; Clioquinol; Drug Resistance, Neoplasm; Humans; Hydroxyquinolines; Lactones; Neoplasms; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Threonine; Ubiquitinated Proteins; Ubiquitination | 2011 |
Clinical and marketed proteasome inhibitors for cancer treatment.
Topics: Boron Compounds; Boronic Acids; Bortezomib; Glycine; Humans; Lactones; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Structure-Activity Relationship; Threonine | 2013 |
13 other study(ies) available for pyrazines and threonine
| Article | Year |
|---|---|
Pyrazine formation from serine and threonine.
Topics: Flame Ionization; Food Preservation; Gas Chromatography-Mass Spectrometry; Hot Temperature; Humans; Pyrazines; Serine; Threonine | 1999 |
Phosphorylation of AML1/RUNX1 regulates its degradation and nuclear matrix association.
Topics: Animals; Boronic Acids; Bortezomib; Core Binding Factor Alpha 2 Subunit; DNA-Binding Proteins; Immunoprecipitation; Mice; Mice, Knockout; Mutation; Nuclear Matrix; Phosphorylation; Protease Inhibitors; Proto-Oncogene Proteins; Pyrazines; Serine; Threonine; Transcription Factors; Transcription, Genetic; Ubiquitin | 2005 |
Dual alterations in casein kinase I-epsilon and GSK-3beta modulate beta-catenin stability in hyperproliferating colonic epithelia.
Topics: Animals; Axin Protein; beta Catenin; Boronic Acids; Bortezomib; Casein Kinase 1 epsilon; Cell Nucleus; Citrobacter rodentium; Colon; Cyclic AMP Response Element-Binding Protein; Cytoskeleton; DNA; Enterobacteriaceae Infections; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hyperplasia; Immunoprecipitation; Intestinal Mucosa; Mice; Phosphorylation; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Binding; Protein Kinase C; Pyrazines; Repressor Proteins; Serine; TCF Transcription Factors; Threonine; Transcription Factor 7-Like 2 Protein | 2007 |
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Endothelial Cells; Enzyme Inhibitors; Humans; Macrophage Colony-Stimulating Factor; Mice; Mice, Nude; Multiple Myeloma; Neoplasms; NF-kappa B; Osteogenesis; Proteasome Inhibitors; Pyrazines; RANK Ligand; Threonine; Treatment Outcome; Ubiquitin; Xenograft Model Antitumor Assays | 2008 |
The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Death; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Male; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Threonine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Drugs: More shots on target.
Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Glycine; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide; Threonine | 2011 |
Analysing properties of proteasome inhibitors using kinetic and X-ray crystallographic studies.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Crystallography, X-Ray; Drug Design; Enzyme Inhibitors; Lactones; Multiple Myeloma; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Saccharomyces cerevisiae; Threonine | 2012 |
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.
Topics: Antineoplastic Agents; Biopsy; Carcinoma, Renal Cell; Disease Progression; Drug Resistance, Neoplasm; Heterozygote; Humans; In Situ Hybridization, Fluorescence; Kidney Neoplasms; Male; Methionine; Middle Aged; Point Mutation; Proto-Oncogene Proteins c-met; Pyrazines; Receptor Protein-Tyrosine Kinases; Sequence Analysis, DNA; Threonine; Treatment Failure; Triazoles | 2013 |
Pyrazines from bacteria and ants: convergent chemistry within an ecological niche.
Topics: Animals; Ants; Ecosystem; Gas Chromatography-Mass Spectrometry; Pheromones; Pyrazines; Serratia marcescens; Sodium Acetate; Threonine | 2018 |
An Alkylpyrazine Synthesis Mechanism Involving l-Threonine-3-Dehydrogenase Describes the Production of 2,5-Dimethylpyrazine and 2,3,5-Trimethylpyrazine by Bacillus subtilis.
Topics: Acetone; Acetyl Coenzyme A; Acetyltransferases; Alcohol Oxidoreductases; Bacillus subtilis; Catalysis; Flavoring Agents; Glycine; Pyrazines; Threonine | 2019 |
[Biosynthesis of 2,5-dimethylpyrazine from L-threonine by whole-cell biocatalyst of recombinant Escherichia coli].
Topics: Escherichia coli; Lactococcus; Metabolic Engineering; Pyrazines; Threonine | 2021 |
Redistribution of Intracellular Metabolic Flow in
Topics: Carbon; Escherichia coli; Metabolic Engineering; Pyrazines; Threonine | 2021 |
BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Benzamides; Cell Line; Cell Line, Tumor; Chickens; Chlorocebus aethiops; COS Cells; Cysteine; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Mutation; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Threonine | 2021 |